News
We always have something going on at Juno.
Want to keep up with our most recent developments?
Have a read of our latest news, new product launches and business news.
Filter News by:

Juno Pharmaceuticals appointed as Fresenius Kabi’s exclusive distribution partner for IDACIO® (adalimumab)

We are pleased to announce that Fresenius Kabi Australia Pty Limited (Fresenius Kabi) has appointed Juno Pharmaceuticals (Juno) as their exclusive distribution partner for IDACIO® (adalimumab) (rch) 40 mg solution for injection pre-filled pen & pre-filled syringe. Read more

Celltrion Healthcare Australia and Juno Pharmaceuticals Australia Partner on Biosimilars

Celltrion Healthcare Australia (Celltrion) and Juno Pharmaceuticals (Juno) have entered in to a co-marketing partnership, covering the biosimilar products Herzuma (biosimilar trastuzumab), and Truxima (biosimilar rituximab). Read more

Juno Pharmaceuticals Acquires Noradrenaline 2 mg/2 mL & 4 mg/4 mL from Mayne Pharma

MELBOURNE, AUSTRALIA – Juno Pharmaceuticals is pleased to announce the acquisition of noradrenaline 2 mg/2 mL and 4 mg/4 mL concentrated injection from Mayne Pharma; an important addition to Juno’s growing range of vasopressors and critical care medicines. Read more

Juno Pharmaceuticals Launches Schedule 3 Naloxone Hydrochloride

Juno Pharmaceuticals is excited to announce the launch of Junalox (naloxone hydrochloride) 400 mcg/1 mL solution for injection, the first product of its type registered as a Schedule 3 - Pharmacist Only Medicine. Read more

Juno Acquires Local Portfolio of Essential Injectable Medicines from AstraZeneca

MELBOURNE, AUSTRALIA – Juno Pharmaceuticals Pty Ltd is pleased to announce the acquisition of a local portfolio of essential injectable medicines from AstraZeneca Pty Ltd.  This acquisition will see Juno’s product range grow to over 60 molecules, focussed mainly in the hospital segment. Read more